{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:55:47Z","timestamp":1770526547087,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.1093\/jac\/dki355","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T00:13:39Z","timestamp":1128039219000},"page":"923-929","source":"Crossref","is-referenced-by-count":157,"title":["Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies"],"prefix":"10.1093","volume":"56","author":[{"given":"Andrew F.","family":"Shorr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,9,29]]},"reference":[{"key":"key\n\t\t\t\t20171013023445_B1","doi-asserted-by":"crossref","unstructured":"Solomon S, Horan T, Andrus M et al. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control2003; 31: 481\u201398.","DOI":"10.1016\/j.ajic.2003.09.002"},{"key":"key\n\t\t\t\t20171013023445_B2","doi-asserted-by":"crossref","unstructured":"Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol1999; 20: 408\u201311.","DOI":"10.1086\/501641"},{"key":"key\n\t\t\t\t20171013023445_B3","doi-asserted-by":"crossref","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis2003; 36: 53\u20139.","DOI":"10.1086\/345476"},{"key":"key\n\t\t\t\t20171013023445_B4","doi-asserted-by":"crossref","unstructured":"Hartstein AI, Mulligan ME, Morthland VH et al. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol1992; 30: 670\u20134.","DOI":"10.1128\/JCM.30.3.670-674.1992"},{"key":"key\n\t\t\t\t20171013023445_B5","doi-asserted-by":"crossref","unstructured":"Johnson LB, Almoujahed MO, Ilg K et al. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis2003; 35: 782\u20139.","DOI":"10.1080\/00365540310016682"},{"key":"key\n\t\t\t\t20171013023445_B6","doi-asserted-by":"crossref","unstructured":"Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore)2003; 82: 333\u20139.","DOI":"10.1097\/01.md.0000091184.93122.09"},{"key":"key\n\t\t\t\t20171013023445_B7","doi-asserted-by":"crossref","unstructured":"Fowler VG Jr, Kong LK, Corey GR et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis1999; 179: 1157\u201361.","DOI":"10.1086\/314712"},{"key":"key\n\t\t\t\t20171013023445_B8","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis1999; 29: 1171\u20137.","DOI":"10.1086\/313440"},{"key":"key\n\t\t\t\t20171013023445_B9","doi-asserted-by":"crossref","unstructured":"Rubinstein E, Cammarata S, Oliphant T et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis2001; 32: 402\u201312.","DOI":"10.1086\/318486"},{"key":"key\n\t\t\t\t20171013023445_B10","doi-asserted-by":"crossref","unstructured":"Wunderink RG, Cammarata SK, Oliphant TH et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther2003; 25: 980\u201392.","DOI":"10.1016\/S0149-2918(03)80118-2"},{"key":"key\n\t\t\t\t20171013023445_B11","doi-asserted-by":"crossref","unstructured":"Kollef MH, Rello J, Cammarata SK et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med2004; 30: 388\u201394.","DOI":"10.1007\/s00134-003-2088-1"},{"key":"key\n\t\t\t\t20171013023445_B12","unstructured":"Weigelt JA, Itani KM, Lau WK et al. Linezolid vs vancomycin in the treatment of complicated skin and soft tissue infections (CSSTI): clinically significant outcome differences. In: Programs and Abstracts of the 40th Annual Meeting of the Infectious Disease Society of America, Chicago, IL, 2002. Abstract 314. Infectious Disease Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171013023445_B13","doi-asserted-by":"crossref","unstructured":"Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis2002; 34: 1481\u201390.","DOI":"10.1086\/340353"},{"key":"key\n\t\t\t\t20171013023445_B14","unstructured":"Stevens DL, Harrison M, Graham DR et al. Linezolid (LZD) IV\/PO vs. Vancomycin (Vanco) IV for the treatment of suspected or proven methicillin-resistant Staphylococcus spp. (MRSS) infections: a second randomized, open-label, clinical trial. In: Programs and Abstracts of the 40th Annual Meeting of the Infectious Disease Society of America, Chicago, IL, 2002. Abstract 181. Infectious Disease Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171013023445_B15","doi-asserted-by":"crossref","unstructured":"Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials1996; 17: 1\u201312.","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"key\n\t\t\t\t20171013023445_B16","doi-asserted-by":"crossref","unstructured":"Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis2004; 38: 448\u201351.","DOI":"10.1086\/381093"},{"key":"key\n\t\t\t\t20171013023445_B17","doi-asserted-by":"crossref","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol2004; 42: 2398\u2013402.","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"key\n\t\t\t\t20171013023445_B18","doi-asserted-by":"crossref","unstructured":"Moise PA, Forrest A, Bhavnani SM et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm2000; 57 Suppl 2: S4\u20139.","DOI":"10.1093\/ajhp\/57.suppl_2.S4"},{"key":"key\n\t\t\t\t20171013023445_B19","doi-asserted-by":"crossref","unstructured":"Schentag JJ. Antimicrobial action and pharmacokinetics\/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother1999; 11: 426\u201339.","DOI":"10.1179\/joc.1999.11.6.426"},{"key":"key\n\t\t\t\t20171013023445_B20","doi-asserted-by":"crossref","unstructured":"Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis1994; 18: 544\u20136.","DOI":"10.1093\/clinids\/18.4.544"},{"key":"key\n\t\t\t\t20171013023445_B21","unstructured":"Gilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy, 31st edn. Hyde Park, VT: Antimicrobial Therapy, Inc, 2001."},{"key":"key\n\t\t\t\t20171013023445_B22","doi-asserted-by":"crossref","unstructured":"Cometta A, Kern WV, De Bock R et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin\u2013tazobactam monotherapy. Clin Infect Dis2003; 37: 382\u20139.","DOI":"10.1086\/376637"},{"key":"key\n\t\t\t\t20171013023445_B23","doi-asserted-by":"crossref","unstructured":"Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother2003; 47: 1824\u201331.","DOI":"10.1128\/AAC.47.6.1824-1831.2003"},{"key":"key\n\t\t\t\t20171013023445_B24","doi-asserted-by":"crossref","unstructured":"Nasraway SA, Shorr AF, Kuter DJ et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis2003; 37: 1609\u201316.","DOI":"10.1086\/379327"},{"key":"key\n\t\t\t\t20171013023445_B25","doi-asserted-by":"crossref","unstructured":"Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy2001; 21: 1010\u20133.","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"key\n\t\t\t\t20171013023445_B26","doi-asserted-by":"crossref","unstructured":"Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis2003; 36: 159\u201368.","DOI":"10.1086\/345744"},{"key":"key\n\t\t\t\t20171013023445_B27","doi-asserted-by":"crossref","unstructured":"Rao N, Ziran BH, Wagener MM et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis2004; 38: 1058\u201364.","DOI":"10.1086\/382356"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/5\/923\/2654778\/dki355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:08:17Z","timestamp":1586477297000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/5\/923\/893239\/Linezolid-versus-vancomycin-for-Staphylococcus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,29]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,9,29]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki355","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,11]]},"published":{"date-parts":[[2005,9,29]]}}}